drugset / Trial / NCT01225380
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®). Additionally, the efficacy and safety of 24 weeks of GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) will be evaluated.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-01
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GS-9256 | Small molecule | 150 mg | — |
| Subject | Tegobuvir | Small molecule | 20 mg | — |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Other |
| Comparator | Ribavirin | Small molecule | 1000 mg | — |
| Comparator | Ribavirin | Small molecule | 1200 mg | — |